Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: A single-institution experience of 144 patients

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1079-1086

  Gielda, Benjamin T ^a   Marsh, James C ^a   Zusag, Thomas W ^a   Faber, L Penfield ^a   Liptay, Michael ^a   Basu, Sanjib ^a   Warren, William H ^a   Jo Fidler, Mary ^a   Batus, Marta ^a   Abrams, Ross A ^a   Bonomi, Philip ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Combined modality therapy; Locally advanced NSCLC; Poor risk; Split course chemoradiotherapy; Treatment interruptions

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ACUTE DISEASE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; SPLIT COURSE CHEMORADIOTHERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES;

EID: 79958156534     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182199a7c     Document Type: Article

References (30)

1. American Cancer Society Cancer Statistics 2009. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. Accessed July 30, 2009.
2. American Joint Committee on Cancer Staging Manual, 6th Ed. Chicago, Springer Publishing, 2002.
3. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-1881. (Pubitemid 17072411)
4. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992;84:58.
5. Dillman RO, Seagren SL, Prospert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-945. (Pubitemid 20332333)
6. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699. (Pubitemid 29415225)
7. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891.
8. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiotherapy for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2003;22:Abstr 2499.
9. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-386.
10. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704. (Pubitemid 46797950)
11. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5760.
12. Kiura K, Takigawa N, Segawa Y, et al. Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2008;26:Abstr 7515.
13. Davies AM, Chansky K, Lau DHM, et al. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol 2006;24:5242-5246. (Pubitemid 46631368)
14. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000;48:1475-1482.
15. Ready N, Jänne PA, Bogart J, et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia Group B (CALGB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 2010;5:1382-1390.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
18. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist, 6th Ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006.
19. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16. (Pubitemid 30488207)
20. Saunders MI, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicenter trial. Radiother Oncol 1999;52:137-148. (Pubitemid 29461081)
21. Petereit DG, Sarkaria JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1301-1307.
22. Begg AC, Hofland I, Van Glabekke M, et al. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin Radiat Oncol 1992;2:22-25.
23. Lau DH, Crowley JJ, Gandara DR, et al. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 1998;16: 3078-3081. (Pubitemid 28417429)
24. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 2010;10:50.
25. Blackstock AW, Socinski MA, Bogart J, et al; Cancer and Leukemia Group B. Induction plus concurrent chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy in stage III non-small cell lung cancer. Preliminary report of Cancer and Leukemia Group B (CALGB) 30105. Proc Am Soc Clin Oncol 2006;24(18S):Abstr 7042.
26. Lee CB, Socinski A, Lin L, et al. High-dose 3D chemoradiotherapy in stage III non-small cell lung cancer (NSCLC) at the University of North Carolina: long-term follow up and late complications. Proc Am Soc Clin Oncol 2006;24(18S):Abstr 7145.
27. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients withinoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Rad Oncol Biol Phys 2005;63:324-333. (Pubitemid 41317147)
28. Schild S, McGinnis WL, Graham D, et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresect-able non-small cell lung cancer. Int J Rad Oncol Biol Phys 2006;65: 1106-1111.
29. Spoelstra FO, Pantarotto JR, van Sörnsen de Koste JR, et al. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. Int J Radiat Oncol Biol Phys 2009;75:1092-1097.
30. Feng M, Kong FM, Gross M, et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys 2009;73:1228-1234.